Figure 6 from Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors
Year: 2025
Type: other
Abstract: TAC01-CLDN18.2 lacks activity against primary cells representing CLDN18.2-negative normal human tissues. Top, CLDN18.2 mRNA analysis by ddPCR in cancer and human primary cells, as indicated. Data are presented as percent relative to levels in N87CLDN18.2 cells (100%). Center/bottom, Flow cytometry analysis measuring proportions of T cells expressing surface CD69 (center) and intracellular cytokines (bottom) determined after a 4-hour coculture of CLDN18.2-TAC T cells with target cells. Data are normalized to data obtained from NTD T cells cocultures to correct for background activity and are plotted relative to values in N87CLDN18.2 cells (100%). Data are shown as averages with SDs derived from experiments done with four TAC01-CLDN18.2 products manufactured from three separate donors. CD69 and all cytokines were significantly elevated in T cells cocultured with OE19 target cells compared with the N87 negative controls or all other human cell models. There was no significant difference between the N87 negative control and any of the other human cell models (statistical data are shown in Supplementary Table S9). ND, not detected.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4406227727